Thomas R. Staab II is President & CFO +1 at BIOCRYST PHARMACEUTICALS INC (BCRX). They have made 19 open-market trades across 2 companies since 2014, most recently 2026-08-31.
CIK 0000882796
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $9K since 2022, against 18 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| LNSR | BUY | 2022-12-06 | 2022-12-07 | $3.16 | $9K | -7.5% | -17.8% | -2.2% |
| BCRX | SELL | 2019-05-16 | 2019-05-20 | $7.65 | $75K | -3.8% | -1.1% | -26.4% |
| BCRX | SELL | 2019-05-14 | 2019-05-16 | $7.81 | $92K | -60.9% | -51.5% | -63.8% |
| BCRX | SELL | 2019-05-09 | 2019-05-13 | $7.67 | $224K | -54.0% | -54.5% | -65.6% |
| BCRX | SELL | 2019-05-02 | 2019-05-06 | $7.54 | $126K | -5.4% | -58.3% | -64.5% |
| BCRX | SELL | 2019-04-04 | 2019-04-08 | $8.81 | $66K | -6.8% | -8.1% | -57.1% |
| BCRX | SELL · 10b5-1 | 2019-01-28 | 2019-01-30 | $9.85 | $49K | +6.2% | -1.0% | -14.6% |
| BCRX | SELL | 2018-12-04 | 2018-12-06 | $9.45 | $37K | -14.8% | -2.8% | -10.5% |
| BCRX | SELL | 2018-11-21 | 2018-11-26 | $9.08 | $64K | -4.6% | -12.7% | -7.4% |
| BCRX | SELL · 10b5-1 | 2018-11-21 | 2018-11-26 | $9.51 | $81K | -4.6% | -12.7% | -7.4% |
| BCRX | SELL | 2018-11-19 | 2018-11-21 | $8.67 | $97K | -3.5% | -21.3% | -3.0% |
| BCRX | SELL | 2018-11-07 | 2018-11-09 | $8.11 | $204K | +19.6% | +17.8% | +17.3% |
| BCRX | SELL · 10b5-1 | 2018-11-05 | 2018-11-07 | $8.00 | $2K | +4.1% | +11.3% | +15.0% |
| BCRX | SELL | 2018-11-02 | 2018-11-06 | $7.81 | $142K | +2.1% | +16.1% | +10.8% |
| BCRX | SELL · 10b5-1 | 2018-10-19 | 2018-10-23 | $7.45 | $23K | +13.5% | +32.8% | +26.8% |
| BCRX | SELL · 10b5-1 | 2018-10-02 | 2018-10-04 | $7.24 | $71K | +4.2% | +14.8% | +23.0% |
| BCRX | SELL · 10b5-1 | 2017-03-20 | 2017-03-22 | $9.20 | $30K | -2.6% | -23.6% | -29.8% |
| BCRX | SELL · 10b5-1 | 2017-03-10 | 2017-03-14 | $9.06 | $29K | +5.1% | -19.3% | -35.8% |
| BCRX | SELL · 10b5-1 | 2017-03-08 | 2017-03-10 | $8.43 | $55K | -4.2% | -19.3% | -37.3% |
| BCRX | SELL · 10b5-1 | 2017-03-06 | 2017-03-08 | $7.90 | $26K | +16.2% | -8.3% | -32.1% |
| BCRX | SELL · 10b5-1 | 2016-12-19 | 2016-12-21 | $7.45 | $24K | +4.6% | -9.6% | +26.0% |
| BCRX | SELL | 2016-08-11 | 2016-08-15 | $5.18 | $30K | -11.6% | -8.2% | +22.4% |
| BCRX | SELL | 2016-08-09 | 2016-08-11 | $4.43 | $129K | -10.8% | -15.6% | -3.5% |
| BCRX | SELL | 2015-12-21 | 2015-12-22 | $10.86 | $33K | -26.4% | -30.2% | -72.6% |
| BCRX | SELL | 2015-12-17 | 2015-12-18 | $10.49 | $31K | -26.4% | -30.6% | -74.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.